Trial Profile
A Phase IIIb Multicenter Study With a 12-week Double-blind, Placebo-controlled, Randomized Period Followed by an Open-label, Extension Phase Evaluating Safety/Efficacy of Certolizumab Pegol Given to Patients With Active Rheumatoid Arthritis.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Oct 2021
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Acronyms REALISTIC
- Sponsors UCB Pharma Inc
- 25 Aug 2012 Results published in the Rheumatology.
- 09 Jun 2012 Relationship between timing and magnitude of initial response and likelihood of low disease activity at week 28 results presented at the 13th Annual Congress of the European League Against Rheumatism.
- 08 Jun 2012 Post-hoc analysis data of the phase III REALISTIC trial in Rheumatoid arthritis presented at the 13th Annual Congress of the European League Against Rheumatism (EULAR-2012), according to an UCB media release.